BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campbell EJ, Norman A, Bonomo Y, Lawrence AJ. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial. Brain Res 2020;1728:146597. [PMID: 31837287 DOI: 10.1016/j.brainres.2019.146597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Barson JR. The role of neuropeptides in drug and ethanol abuse: Medication targets for drug and alcohol use disorders. Brain Research 2020;1740:146876. [DOI: 10.1016/j.brainres.2020.146876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Reference Citation Analysis]
4 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
5 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Morley KC, Perry CJ, Watt J, Hurzeler T, Leggio L, Lawrence AJ, Haber P. New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opin Pharmacother 2021;22:1291-303. [PMID: 33615945 DOI: 10.1080/14656566.2021.1892641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]